CRC
53 programs · 52 companies
Programs
53
Companies
52
Trials
50
MOAs
37
PRMT5iVEGFiWRNiALKiFGFRiPI3KiJAK1/2iEZH2iBCL-2iTNFi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Approved | BCL-2 | ||
| Ceviderotide | Preclinical | IL-13 | ||
| AMG-2752 | Preclinical | MDM2 | ||
| Sovacapivasertib | Phase 3 | WEE1 | ||
| SRP-9822 | Phase 3 | SOS1 | ||
| Fixaosocimab | Phase 2/3 | SOS1 | ||
| CGO-9628 | Phase 2/3 | AuroraA | ||
| ARC-1235 | Phase 3 | GPRC5D | ||
| Gozebrutinib | Approved | Tau | ||
| MD-IIT-621 | Phase 2/3 | USP1 | ||
| SCO-5362 | NDA/BLA | USP1 | ||
| QUO-8015 | Phase 1 | TROP-2 | ||
| Tirazanubrutinib | Approved | B7-H3 | ||
| Olparelsin | Preclinical | FcRn | ||
| RAP-8975 | Phase 2 | TROP-2 | ||
| Rilubrutinib | Phase 1 | FcRn | ||
| Doxaderotide | Phase 1/2 | FcRn | ||
| PMC-7054 | Phase 2 | Tau | ||
| Tezesotorasib | Preclinical | SHP2 | ||
| RLY-2544 | Preclinical | FLT3 | ||
| Adagrainavolisib | Phase 2/3 | FcRn | ||
| IMV-1446 | Approved | MDM2 | ||
| AVI-386 | Phase 1/2 | HER2 | ||
| Tixacilimab | Phase 1/2 | FcRn | ||
| Polarasimod | Phase 3 | GPRC5D | ||
| Polazumab | Phase 3 | KRASG12D | ||
| Rilufutibatinib | NDA/BLA | CD47 | ||
| KAR-2338 | Preclinical | DLL3 | ||
| CEL-1794 | Approved | PARP | ||
| Rilufutibatinib | Phase 3 | GPRC5D | ||
| FDM-9341 | Phase 2/3 | JAK1 | ||
| Riluratamab | Preclinical | KRASG12C | ||
| Tiravorutinib | Preclinical | GLP-1R | ||
| Mirinesiran | Phase 2 | FcRn | ||
| Voxafutibatinib | Phase 1/2 | GPRC5D | ||
| Olpasertib | Phase 2 | MALT1 | ||
| PPL-6055 | Phase 2/3 | Nectin-4 | ||
| SVA-6795 | NDA/BLA | CDK4/6 | ||
| IMV-2493 | Phase 2 | PSMA | ||
| Datorasimod | Phase 2/3 | CDK4/6 | ||
| DBV-5518 | Phase 1 | USP1 | ||
| Capimavacamten | Phase 1 | TIGIT | ||
| NEO-620 | Phase 2/3 | IL-13 | ||
| Zenotuximab | Phase 2/3 | FGFR | ||
| 415-7241 | Phase 1 | HER2 | ||
| Doxacapivasertib | Phase 2/3 | Aβ | ||
| Fixalucimab | Preclinical | TYK2 | ||
| NAT-IIT-338 | Approved | BTK | ||
| DEC-1380 | Preclinical | PD-L1 | ||
| IDX-6209 | Preclinical | CGRP | ||
| Surarasimod | Phase 2 | BET | ||
| Rimarelsin | Phase 3 | FLT3 | ||
| Datozumab | Phase 1/2 | PCSK9 |
Trials (50)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03802615 | RHH-8550 | Approved | Completed |
| NCT06769244 | RHH-8550 | Approved | Recruiting |
| NCT05205092 | Ceviderotide | Preclinical | Recruiting |
| NCT08244793 | AMG-2752 | Preclinical | Not yet recr... |
| NCT07697567 | Sovacapivasertib | Phase 3 | Not yet recr... |
| NCT08722519 | Sovacapivasertib | Phase 3 | Terminated |
| NCT05054122 | SRP-9822 | Phase 3 | Not yet recr... |
| NCT08201173 | Fixaosocimab | Phase 2/3 | Recruiting |
| NCT05620211 | ARC-1235 | Phase 3 | Not yet recr... |
| NCT03326700 | Gozebrutinib | Approved | Completed |
| NCT05693685 | Gozebrutinib | Approved | Terminated |
| NCT05777556 | Gozebrutinib | Approved | Recruiting |
| NCT04269680 | MD-IIT-621 | Phase 2/3 | Active |
| NCT06625129 | QUO-8015 | Phase 1 | Completed |
| NCT05881509 | Tirazanubrutinib | Approved | Not yet recr... |
| NCT05635350 | Rilubrutinib | Phase 1 | Recruiting |
| NCT08966725 | Rilubrutinib | Phase 1 | Recruiting |
| NCT05103753 | Doxaderotide | Phase 1/2 | Active |
| NCT07889929 | Doxaderotide | Phase 1/2 | Not yet recr... |
| NCT04153089 | PMC-7054 | Phase 2 | Active |